华东医药(000963.SZ)：索米妥昔单抗注射液获得药品补充申请批准通知书

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration (NMPA) for the supplemental application of the drug Somatuzumab Injection, transitioning from conditional approval to regular approval [1] Group 1 - The drug Somatuzumab Injection is marketed under the name ELAHERE® with the research code HDM2002 [1] - The approval signifies a significant regulatory milestone for Huadong Medicine, enhancing its product portfolio and market position [1]